{
    "clinical_study": {
        "@rank": "63938", 
        "arm_group": [
            {
                "arm_group_label": "High Concentration Liquid Formulation (HCLF)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lyophilized formulation", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single-center, randomized open-label, single-dose, parallel group study will\n      investigate the relative bioavailability of a high concentration liquid formulation (HCLF)\n      versus the reference lyophilized formulation (LyoF) of gantenerumab. Healthy volunteers will\n      be randomized 1:1 to receive single-dose gantenerumab by subcutaneous injection."
        }, 
        "brief_title": "A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female subjects, 40 to 70 years of age inclusive. Healthy status is\n             defined by absence of evidence any active or chronic disease following a detailed\n             medical and surgical history, a complete physical examination including vital signs,\n             12-lead ECG, hematology, blood chemistry, coagulation, serology and urinalysis. Some\n             medical conditions are allowed that are well controlled by single stable medication\n\n          -  A BMI between 18.0 to 30.0 kg/m2 inclusive\n\n          -  Use of highly effective contraception until 6 months after study follow-up visit\n\n          -  Agree not to donate blood or blood products for transfusion for the duration of the\n             study and for one year after their dosing\n\n        Exclusion Criteria:\n\n          -  Suspicion of alcohol or drugs abuse addiction using DSM IV criteria\n\n          -  Regular smoker (> 5 cigarettes, > 1 pipeful or > 1 cigar per day), tobacco users and\n             subjects on nicotine replacement therapy\n\n          -  Prior administration of gantenerumab\n\n          -  Participation in an investigational drug or device study within 60 days before dosing\n\n          -  Donation of blood over 500 mL within three months before dosing\n\n          -  Pregnancy or breast-feeding\n\n          -  Any abnormal skin conditions or potentially obscuring tattoos, pigmentation or\n             lesions in the area intended for subcutaneous injection\n\n          -  Any familial history of early onset Alzheimer's disease\n\n          -  Claustrophobia, presence of pacemakers, aneurysm clips, artificial heart valves, ear\n             implants, or foreign metal objects in the eyes, skin or body which would\n             contraindicate an MRI scan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133937", 
            "org_study_id": "BP29113"
        }, 
        "intervention": [
            {
                "arm_group_label": "High Concentration Liquid Formulation (HCLF)", 
                "description": "Single subcutaneous injection of a high concentration liquid formulation", 
                "intervention_name": "gantenerumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lyophilized formulation", 
                "description": "Single subcutaneous injection of a lyophilized formulation", 
                "intervention_name": "gantenerumab", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66219"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: BP29113 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentration of gantenerumab", 
            "safety_issue": "No", 
            "time_frame": "Up to 13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 21 weeks"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}